# GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company developing immunomodulatory therapies for inflammatory, fibrotic, and autoimmune disorders. The company's approach focuses on targeting Natural Killer T cells to modulate immune responses. Its lead candidate, GRI-0621, is an oral inhibitor of type 1 Natural Killer T cells currently in phase IIa clinical trials for idiopathic pulmonary fibrosis and other severe fibrotic lung diseases. The company also has GRI-0803, an oral agonist of type 2 Natural Killer T cells in preclinical development for autoimmune disorders, alongside GRI-0124 and GRI-0729 for balancing inflammatory immune responses.
The company maintains a proprietary library exceeding 500 compounds supporting its pipeline. GRI Bio operates with a minimal workforce of three full-time employees and is headquartered in La Jolla, California. The company generates no meaningful revenue at present given its clinical-stage status. As a Nasdaq-listed entity, GRI Bio depends on capital markets access and external funding to advance its clinical development programs. The company was founded in 2009 and was previously known as Glycoregimmune, Inc.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-121.80 | $-121.80 | -120.6% | |
| 2024 | $-55.21 | $-55.21 | -95.4% | |
| 2023 | $-28.25 | $-28.25 | -3994.2% | |
| 2022 | $-0.69 | $-0.69 | +51.4% | |
| 2021 | $-1.42 | $-1.42 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-01-30 | 0001824293-26-000033 | SEC ↗ |
| 2024-12-31 | 2025-03-14 | 0001824293-25-000050 | SEC ↗ |
| 2023-12-31 | 2024-03-28 | 0001824293-24-000033 | SEC ↗ |
| 2022-12-31 | 2023-02-24 | 0001824293-23-000016 | SEC ↗ |
| 2021-12-31 | 2022-02-14 | 0001824293-22-000004 | SEC ↗ |
| 2020-12-31 | 2021-03-29 | 0001104659-21-042819 | SEC ↗ |